{"id":178269,"date":"2026-07-31T10:41:22","date_gmt":"2026-07-31T05:11:22","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=178269"},"modified":"2026-07-31T10:41:23","modified_gmt":"2026-07-31T05:11:23","slug":"mankind-pharma-q1-results-fy27-pat-rs-570-cr","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27-pat-rs-570-cr\/","title":{"rendered":"Mankind Pharma Q1 Results FY27: Net Profit at Rs 570 Cr for June 2026 Quarter"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Mankind Pharma Q1 results FY27: Revenue Rs 4,030 Cr. Net profit Rs 570 Cr. Consolidated basis. Stock at Rs 2,576 (-0.65%) on 30 July 2026.<\/em><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27-pat-rs-570-cr\/#Key_Takeaways\" title=\"Key Takeaways\">Key Takeaways<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27-pat-rs-570-cr\/#Mankind_Pharma_Q1_Results_FY27_Key_Numbers_at_a_Glance\" title=\"Mankind Pharma Q1 Results FY27: Key Numbers at a Glance\">Mankind Pharma Q1 Results FY27: Key Numbers at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27-pat-rs-570-cr\/#Mankind_Pharma_Q1_Results_FY27_What_Drove_Revenue\" title=\"Mankind Pharma Q1 Results FY27: What Drove Revenue\">Mankind Pharma Q1 Results FY27: What Drove Revenue<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27-pat-rs-570-cr\/#Mankind_Pharma_Q1_Results_FY27_Profitability_Breakdown\" title=\"Mankind Pharma Q1 Results FY27: Profitability Breakdown\">Mankind Pharma Q1 Results FY27: Profitability Breakdown<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27-pat-rs-570-cr\/#Stock_Price_Reaction_to_the_Mankind_Pharma_Q1_Results_FY27\" title=\"Stock Price Reaction to the Mankind Pharma Q1 Results FY27\">Stock Price Reaction to the Mankind Pharma Q1 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27-pat-rs-570-cr\/#What_the_Mankind_Pharma_Q1_Results_FY27_Mean_for_Investors\" title=\"What the Mankind Pharma Q1 Results FY27 Mean for Investors\">What the Mankind Pharma Q1 Results FY27 Mean for Investors<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27-pat-rs-570-cr\/#Business_Context_Behind_the_Mankind_Pharma_Q1_Results_FY27\" title=\"Business Context Behind the Mankind Pharma Q1 Results FY27\">Business Context Behind the Mankind Pharma Q1 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27-pat-rs-570-cr\/#Key_Things_to_Watch_After_the_Mankind_Pharma_Q1_Results_FY27\" title=\"Key Things to Watch After the Mankind Pharma Q1 Results FY27\">Key Things to Watch After the Mankind Pharma Q1 Results FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27-pat-rs-570-cr\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27-pat-rs-570-cr\/#FAQs_on_Mankind_Pharma_Q1_Results_FY27\" title=\"FAQs on Mankind Pharma Q1 Results FY27\">FAQs on Mankind Pharma Q1 Results FY27<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27-pat-rs-570-cr\/#What_was_Mankind_Pharmas_revenue_in_Q1_results_FY27\" title=\"What was Mankind Pharma&#8217;s revenue in Q1 results FY27?\">What was Mankind Pharma&#8217;s revenue in Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27-pat-rs-570-cr\/#Did_Mankind_Pharma_make_a_profit_or_loss_in_Q1_FY27\" title=\"Did Mankind Pharma make a profit or loss in Q1 FY27?\">Did Mankind Pharma make a profit or loss in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27-pat-rs-570-cr\/#What_was_Mankind_Pharmas_gross_profit_in_Q1_FY27\" title=\"What was Mankind Pharma&#8217;s gross profit in Q1 FY27?\">What was Mankind Pharma&#8217;s gross profit in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27-pat-rs-570-cr\/#When_were_the_Mankind_Pharma_Q1_results_FY27_announced\" title=\"When were the Mankind Pharma Q1 results FY27 announced?\">When were the Mankind Pharma Q1 results FY27 announced?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27-pat-rs-570-cr\/#Did_Mankind_Pharma_shares_go_up_or_down_after_the_Q1_results_FY27\" title=\"Did Mankind Pharma shares go up or down after the Q1 results FY27?\">Did Mankind Pharma shares go up or down after the Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27-pat-rs-570-cr\/#Were_the_Mankind_Pharma_Q1_results_FY27_consolidated_or_standalone\" title=\"Were the Mankind Pharma Q1 results FY27 consolidated or standalone?\">Were the Mankind Pharma Q1 results FY27 consolidated or standalone?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27-pat-rs-570-cr\/#What_should_investors_watch_after_Mankind_Pharmas_Q1_results_FY27\" title=\"What should investors watch after Mankind Pharma&#8217;s Q1 results FY27?\">What should investors watch after Mankind Pharma&#8217;s Q1 results FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/mankind-pharma-q1-results-fy27-pat-rs-570-cr\/#Are_the_Mankind_Pharma_Q1_results_FY27_a_buy_signal\" title=\"Are the Mankind Pharma Q1 results FY27 a buy signal?\">Are the Mankind Pharma Q1 results FY27 a buy signal?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Takeaways\"><\/span><strong>Key Takeaways<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>Mankind Pharma&#8217;s revenue for the June 2026 quarter came in at Rs 4,030 Cr, rose 12.89% year on year from Rs 3,570 Cr.<\/li>\n<li>Mankind Pharma came in at a consolidated net profit of Rs 570 Cr, up 29.15% from Rs 441 Cr in Q1 FY26.<\/li>\n<li>Gross profit was reported at Rs 830 Cr for the quarter.<\/li>\n<li>The stock traded at Rs 2,576 on 30 July 2026, down 0.65% during the session.<\/li>\n<\/ul>\n<p>If you are searching for Mankind Pharma Q1 results FY27, here is the direct answer: Mankind Pharma reported consolidated revenue of Rs 4,030 Cr and a net profit of Rs 570 Cr for the quarter ended 30 June 2026, rose 12.89% year on year from Rs 3,570 Cr. The rest of this article expands on that answer with the full revenue and profit breakdown, what changed compared with Q1 FY26, how the stock reacted, and what to watch next, so you do not need to piece it together from multiple sources.<\/p>\n<p>Prepared by Ankit Jaiswal, Senior Research Analyst at Univest, this review of the Mankind Pharma Q1 results FY27 is based on figures disclosed in the company&#8217;s exchange filing for the June 2026 quarter.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=mankind-pharma-q1-results-fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Mankind_Pharma_Q1_Results_FY27_Key_Numbers_at_a_Glance\"><\/span><strong>Mankind Pharma Q1 Results FY27: Key Numbers at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr style=\"background: #EBF3FB;\">\n<th>Metric<\/th>\n<th>Q1 FY27<\/th>\n<th>Q1 FY26<\/th>\n<th>YoY Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue<\/td>\n<td style=\"text-align: right;\">Rs 4,030 Cr<\/td>\n<td style=\"text-align: right;\">Rs 3,570 Cr<\/td>\n<td style=\"text-align: right;\">12.89%<\/td>\n<\/tr>\n<tr>\n<td>Gross Profit<\/td>\n<td style=\"text-align: right;\">Rs 830 Cr<\/td>\n<td style=\"text-align: right;\">Rs 628 Cr<\/td>\n<td style=\"text-align: right;\">32.22%<\/td>\n<\/tr>\n<tr>\n<td>Net Profit<\/td>\n<td style=\"text-align: right;\">Rs 570 Cr<\/td>\n<td style=\"text-align: right;\">Rs 441 Cr<\/td>\n<td style=\"text-align: right;\">29.15%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All figures in the Mankind Pharma Q1 results FY27 table above are on a consolidated basis for the quarter ended 30 June 2026, compared with Q1 FY26. This is the core data set behind the Mankind Pharma Q1 results FY27 search.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Mankind_Pharma_Q1_Results_FY27_What_Drove_Revenue\"><\/span><strong>Mankind Pharma Q1 Results FY27: What Drove Revenue<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Revenue for <a href=\"https:\/\/univest.in\/stocks\/mankind\/mankind-pharma-ltd-share-price-today\">Mankind Pharma<\/a> in Q1 FY27 rose 12.89% from Rs 3,570 Cr to Rs 4,030 Cr, against Rs 3,570 Cr in Q1 FY26. Anyone comparing Mankind Pharma against its own past performance should treat this as the base number: a company in the pharmaceutical formulations space, this pace of growth reflects demand and pricing trends specific to that segment during the June 2026 quarter.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Mankind_Pharma_Q1_Results_FY27_Profitability_Breakdown\"><\/span><strong>Mankind Pharma Q1 Results FY27: Profitability Breakdown<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Mankind Pharma came in at a consolidated net profit of Rs 570 Cr, up 29.15% from Rs 441 Cr in Q1 FY26 in Q1 FY27. Gross profit for the quarter was Rs 830 Cr, a change of 32.22% from Rs 628 Cr in Q1 FY26.<\/p>\n<p>The broadly consistent movement between gross profit and net profit in the Mankind Pharma Q1 results FY27 suggests the quarter&#8217;s profit performance is being driven mainly by core operations rather than one-off or below-the-line items.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Stock_Price_Reaction_to_the_Mankind_Pharma_Q1_Results_FY27\"><\/span><strong>Stock Price Reaction to the Mankind Pharma Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Mankind Pharma shares traded at Rs 2,576 on 30 July 2026, down 0.65% during the session. If your search intent is specifically about the stock reaction rather than the raw numbers, this is the figure that answers it: the market&#8217;s verdict weighed the revenue and profit results together, alongside broader market conditions on the day.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/sebi-registered-investment-advisor-india\"><strong>Talk to a SEBI Registered Investment Adviser Before You Invest<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_the_Mankind_Pharma_Q1_Results_FY27_Mean_for_Investors\"><\/span><strong>What the Mankind Pharma Q1 Results FY27 Mean for Investors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Mankind Pharma Q1 results FY27 give investors three concrete data points: a revenue base of Rs 4,030 Cr, a net profit of Rs 570 Cr, and a year-on-year growth trajectory that either confirms or challenges the investment thesis for the stock. None of these numbers should be read in isolation from the detailed exchange filing, segment disclosures and management commentary that typically accompany results.<\/p>\n<p>Comparing this quarter with peers in the pharmaceutical formulations space is also useful context. A company can post strong absolute growth and still lag its peer set, or post modest growth that is nonetheless best-in-class for its sector, so relative positioning matters as much as the standalone numbers in the Mankind Pharma Q1 results FY27. Investors who track a basket of names in the same industry will typically get a clearer read on whether this quarter reflects a company-specific story or a broader sector trend.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Business_Context_Behind_the_Mankind_Pharma_Q1_Results_FY27\"><\/span><strong>Business Context Behind the Mankind Pharma Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Mankind Pharma operates in the pharmaceutical formulations space, where demand cycles, input costs and competitive intensity all shape quarterly performance. The Mankind Pharma Q1 results FY27 should be read against these sector-level dynamics rather than as a standalone number, since the same growth rate can carry very different implications depending on the underlying industry conditions.<\/p>\n<p>Quarterly results are unaudited and subject to limited review, so any restatements or exceptional items disclosed in the notes to the Mankind Pharma Q1 results FY27 can shift how the reported profit should be interpreted. Reading the full exchange filing alongside this summary remains the most reliable way to form a complete view, particularly for line items such as other income, exceptional items and tax adjustments that do not always show up in a headline summary.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Things_to_Watch_After_the_Mankind_Pharma_Q1_Results_FY27\"><\/span><strong>Key Things to Watch After the Mankind Pharma Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Sequential trend:<\/strong> Whether the momentum in the Mankind Pharma Q1 results FY27 carries into the September 2026 quarter or proves to be a one-off.<\/li>\n<li><strong>Management commentary:<\/strong> Guidance on demand, margins and capital allocation for the rest of FY27.<\/li>\n<li><strong>Sector conditions:<\/strong> Developments in the pharmaceutical formulations space that could influence input costs, pricing power or competitive intensity.<\/li>\n<li><strong>Corporate actions:<\/strong> Any dividend, capex or strategic announcements accompanying the results that signal management&#8217;s confidence in the outlook.<\/li>\n<li><strong>Balance sheet health:<\/strong> Debt levels, working capital trends and cash flow generation, which together determine how much flexibility Mankind Pharma has to fund future growth.<\/li>\n<\/ul>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track quarterly results, live prices and research updates in one place.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Mankind Pharma Q1 results FY27 show consolidated revenue of Rs 4,030 Cr and a net profit of Rs 570 Cr for the quarter ended 30 June 2026. The quarter&#8217;s profit delivery keeps the near-term earnings narrative broadly intact. As Ankit Jaiswal notes, investors should track the next few quarterly prints and management commentary before drawing firm conclusions, and consult a SEBI registered investment adviser before acting on these results.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 14px 18px; margin-top: 24px;\">\n<p style=\"color: #ffffff; margin: 0;\"><strong>Disclaimer:<\/strong> This article is for educational and informational purposes only and should not be considered investment advice. Revenue, gross profit and net profit figures are sourced from the company&#8217;s exchange filings for the quarter ended 30 June 2026. Stock market investments are subject to risks. Please consult a SEBI registered investment adviser before making any investment decision. Univest Research Analyst SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Mankind_Pharma_Q1_Results_FY27\"><\/span><strong>FAQs on Mankind Pharma Q1 Results FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Mankind_Pharmas_revenue_in_Q1_results_FY27\"><\/span><strong>What was Mankind Pharma&#8217;s revenue in Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Mankind Pharma&#8217;s revenue in Q1 results FY27 was Rs 4,030 Cr, rose 12.89% year on year from Rs 3,570 Cr.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Mankind_Pharma_make_a_profit_or_loss_in_Q1_FY27\"><\/span><strong>Did Mankind Pharma make a profit or loss in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Mankind Pharma reported a net profit of Rs 570 Cr in Q1 results FY27 on a consolidated basis for the quarter ended 30 June 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Mankind_Pharmas_gross_profit_in_Q1_FY27\"><\/span><strong>What was Mankind Pharma&#8217;s gross profit in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Mankind Pharma&#8217;s gross profit in Q1 results FY27 was Rs 830 Cr, against Rs 628 Cr in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"When_were_the_Mankind_Pharma_Q1_results_FY27_announced\"><\/span><strong>When were the Mankind Pharma Q1 results FY27 announced?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Mankind Pharma Q1 results FY27 were announced on 30 July 2026, covering the quarter ended 30 June 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Mankind_Pharma_shares_go_up_or_down_after_the_Q1_results_FY27\"><\/span><strong>Did Mankind Pharma shares go up or down after the Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Mankind Pharma shares traded at Rs 2,576 on 30 July 2026, down 0.65% following the Q1 results FY27.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Were_the_Mankind_Pharma_Q1_results_FY27_consolidated_or_standalone\"><\/span><strong>Were the Mankind Pharma Q1 results FY27 consolidated or standalone?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Mankind Pharma Q1 results FY27 are on a consolidated basis, as reported in the company&#8217;s exchange filing for the June 2026 quarter.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_should_investors_watch_after_Mankind_Pharmas_Q1_results_FY27\"><\/span><strong>What should investors watch after Mankind Pharma&#8217;s Q1 results FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should watch the sequential trend into the September quarter, management commentary, sector-level conditions in the pharmaceutical formulations space, and any corporate action announcements.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Are_the_Mankind_Pharma_Q1_results_FY27_a_buy_signal\"><\/span><strong>Are the Mankind Pharma Q1 results FY27 a buy signal?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Quarterly results are a data point, not a recommendation. Investors should assess valuations, earnings quality and their own risk profile, and consult a SEBI registered investment adviser before investing.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mankind Pharma Q1 results FY27: consolidated net profit at Rs 570 Cr and revenue at Rs 4,030 Cr for the quarter ended June 2026. Direct answer plus full breakdown inside.<\/p>\n","protected":false},"author":34,"featured_media":178264,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3841],"tags":[3802],"class_list":["post-178269","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mutual-funds","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["178264"],"_edit_lock":["1785474686:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["3841"],"rank_math_seo_score":["80"],"rank_math_title":["Mankind Pharma Q1 Results FY27: PAT Rs 570 Cr, Revenue Rs 4,030 Cr"],"rank_math_description":["Mankind Pharma Q1 results FY27: consolidated net profit at Rs 570 Cr and revenue at Rs 4,030 Cr for the quarter ended June 2026. Direct answer plus full breakdown inside."],"rank_math_focus_keyword":["Mankind Pharma Q1 results FY27"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["32322"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/07\/mankind-pharma-q1-results-fy27-pat-rs-570-cr.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/178269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=178269"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/178269\/revisions"}],"predecessor-version":[{"id":178473,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/178269\/revisions\/178473"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/178264"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=178269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=178269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=178269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}